Adjuvant Treatment for Stage III Triple-Negative Breast Cancer
For stage III triple-negative breast cancer, the optimal adjuvant treatment depends critically on whether the patient received neoadjuvant chemotherapy and whether residual disease remains after surgery.
Treatment Algorithm Based on Clinical Scenario
Scenario 1: Residual Disease After Neoadjuvant Chemotherapy
If the patient received neoadjuvant anthracycline- and taxane-based chemotherapy and has residual invasive disease at surgery, offer adjuvant capecitabine 1,250 mg/m² orally twice daily on days 1-14 of a 21-day cycle for 6-8 cycles 1, 2. This recommendation is based on the CREATE-X trial, which demonstrated significant survival benefits in triple-negative breast cancer patients with residual disease:
- Disease-free survival HR 0.70 (95% CI 0.53-0.92)
- Overall survival HR 0.59 (95% CI 0.39-0.90)
- At 10-year follow-up: recurrence-free survival HR 0.53 and OS HR 0.55 1
Additionally, if the patient has a germline BRCA1/2 mutation and residual disease after neoadjuvant chemotherapy, add adjuvant olaparib for 1 year (category 1 recommendation) 2. This can be given concurrently with capecitabine, though sequencing data are limited as patients in the OlympiA trial did not receive capecitabine.
If pembrolizumab was administered with neoadjuvant chemotherapy, continue adjuvant pembrolizumab based on KEYNOTE-522 trial data showing improved event-free survival (HR 0.63,95% CI 0.48-0.82) 3, 2.
Scenario 2: Primary Adjuvant Treatment (No Neoadjuvant Therapy)
For patients undergoing primary surgery without neoadjuvant treatment, administer dose-dense anthracycline and taxane-based chemotherapy 2:
Preferred regimens:
- Dose-dense AC (doxorubicin/cyclophosphamide) followed by weekly paclitaxel - this is superior to every-3-week paclitaxel schedules
- AC followed by docetaxel every 3 weeks
- TC (docetaxel/cyclophosphamide) for 4-6 cycles if anthracyclines are contraindicated 2
For patients with germline BRCA1/2 mutations and ≥pT2 or ≥pN1 disease after adjuvant chemotherapy, add olaparib for 1 year 2.
Critical Caveats and Pitfalls
Capecitabine Toxicity Considerations
The capecitabine dosage of 1,250 mg/m² twice daily is associated with higher toxicity in patients ≥65 years old 1. Hand-foot syndrome occurs in 73% of patients (11% grade 3) 1. Dose reduction may be necessary in elderly patients.
Immunotherapy Considerations
Do NOT use nivolumab plus ipilimumab as adjuvant treatment for residual disease - the BREASTIMMUNE-03 trial showed no DFS benefit compared to capecitabine (HR 0.84,95% CI 0.45-1.59) with significantly increased immune-mediated adverse events (38% treatment discontinuation rate) 4.
Pembrolizumab Eligibility
Adjuvant pembrolizumab is only indicated if it was part of the neoadjuvant regimen. The benefit is seen regardless of PD-L1 status 3. However, 44% of patients experience immune-related adverse reactions 3.
Real-World Evidence Considerations
While CREATE-X showed clear benefit, some real-world studies have failed to replicate these results 5. However, the most recent Korean real-world study (2025) confirmed improved 3-year distant disease-free survival (86.3% vs 74.4%, p=0.019) and overall survival (93.3% vs 83.8%, p=0.032) with adjuvant capecitabine 6, supporting guideline recommendations.
Quality of Life and Safety Profile
The NCCN and ASCO guidelines explicitly state that benefits outweigh harms for capecitabine in this setting 1. The survival benefit (45% reduction in death risk for TNBC) justifies the toxicity profile, though careful patient selection and monitoring are essential.
For patients who achieved pathologic complete response after neoadjuvant therapy, no additional adjuvant chemotherapy beyond completion of the planned regimen is needed, though adjuvant pembrolizumab should continue if started neoadjuvantly 2, 3.